Avalo Posts Wider Q2 Loss, Positive Phase 2 Data, and Cash Runway Through 2029
AVTX has more than doubled off its 52-week low of $7.87 on light trading volume (0.4× avg).
Summary
Avalo Therapeutics reported a wider Q2 net loss of $36.4M, but ended the quarter with $472.2M in cash, funding operations into 2029. Positive Phase 2 data for lead drug abdakibart supports a Phase 3 program.
Key Events · Earnings and Guidance · AVTX
-
Q2 Net Loss Widens
Net loss of $36.4M vs $20.8M in Q2 2025, driven by a $10M milestone expense for abdakibart's Phase 3 trial and a $6.6M non-cash contingent consideration charge.
-
Cash Runway Extended into 2029
Cash and investments of $472.2M as of June 30, 2026, following a $405M equity offering in May 2026, funds operations into 2029.
-
Positive Phase 2 LOTUS Data
Abdakibart met primary endpoint in Phase 2 LOTUS trial for hidradenitis suppurativa, with 42.5% absolute improvement in HiSCR75 response rate vs placebo (25.6%).
-
Phase 3 Milestone Accrued
$10M development milestone payable to Lilly upon dosing first patient in Phase 3 trial of abdakibart was deemed probable and expensed in Q2.
Analysis · AVTX · Life Sciences
Avalo's Q2 2026 net loss widened to $36.4M from $20.8M a year ago, driven by a $10M milestone expense for abdakibart's Phase 3 trial and a $6.6M non-cash charge from the AlmataBio buyout. The company ended the quarter with $472.2M in cash and investments, extending its runway into 2029. Positive Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa supports advancement into a registrational Phase 3 program. Insider trading plans were adopted or modified by the CEO and CFO, while the Chief Legal Officer terminated his plan.
At the time of this filing, AVTX was trading at $18.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $996.7M. The 52-week trading range was $7.87 to $24.27. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.